Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dimebutic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimebutic Acid SCHEMBL8383026 | 0.94 | FFAR3 (0.35) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Dimebutic Acid SCHEMBL13517329 | 0.94 | — | — | |
| Dimebutic Acid SCHEMBL28581861 | 0.94 | FFAR3 (0.35) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Dimebutic Acid SCHEMBL8383022 | 0.94 | FFAR3 (0.35) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Dimebutic Acid SCHEMBL2990627 | 0.94 | — | — | |
| Dimebutic Acid SCHEMBL8748037 | 0.94 | FFAR3 (0.35) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Dimebutic Acid SCHEMBL28444778 | 0.94 | FFAR3 (0.35) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Dimebutic Acid SCHEMBL1964556 | 0.94 | — | — | |
| Dimebutic Acid SCHEMBL15022227 | 0.94 | — | — | |
| Dimebutic Acid SCHEMBL1055425 | 0.94 | FFAR3 (0.35) | FFAR3HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018176-B2 | Inducers of hematopoiesis and fetal globin production for treatment of cytopenias and hemoglobin disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-28 | — | — | US | disclosed |
| WO-2015026939-A1 | CHEMICAL INDUCERS OF FETAL HEMOGLOBIN | PHOENICIA BIOSCIENCES, INC. (US) | 2015-02-26 | — | — | WO | disclosed |
| US-8618068-B2 | Methods and low dose regimens for treating red blood cell disorders | TRUSTEES OF BOSTON UNIVERSITY (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2509418-A1 | METHODS AND LOW DOSE REGIMENS FOR TREATING RED BLOOD CELL DISORDERS | Hemaquest Pharmaceuticals, Inc. (US) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011072086-A9 | METHODS AND LOW DOSE REGIMENS FOR TREATING RED BLOOD CELL DISORDERS | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2012-09-27 | — | — | WO | disclosed |
| US-20110251149-A1 | METHODS AND LOW DOSE REGIMENS FOR TREATING RED BLOOD CELL DISORDERS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011072086-A1 | METHODS AND LOW DOSE REGIMENS FOR TREATING RED BLOOD CELL DISORDERS | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251149-A1 | METHODS AND LOW DOSE REGIMENS FOR TREATING RED BLOOD CELL DISORDERS | HBB, HBZ, HBG2 | FFAR3 2971/4885HDAC3 7/4885HDAC1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.